Suzanne Feeney, PharmD, explains why expanding clinical services—from immunizations to chronic disease management—is a critical growth strategy for independent pharmacies navigating reimbursement pressures and shifting legislation.

As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.

Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about the FDA's expansion of over-the-counter naloxone access, remaining barriers to availability, and the critical role pharmacists play in overdose prevention and patient education.

A compliance expert breaks down the FDA's move to exclude glucagon-like peptide-1 (GLP-1) drugs from the 503B bulk's list and what it means for pharmacists and patients.

Shahida Choudhry, PharmD, discusses earning McKesson ideaShare's inaugural Trailblazer Award, building an integrated primary care and pharmacy model, and using advocacy and social media to elevate independent pharmacy.

Marijuana’s move to Schedule III has reignited a long-standing contradiction.